In a wide-ranging interview, Abe Ceesay detailed how Rapport built an investor syndicate and why the company is confident it can join the ranks of successful, commercial-stage brain drugmakers.

Original title: “Rapport ‘fully prepared’ to launch seizure drug solo, CEO says”

After the FDA flagged patient deaths linked to Amgen's rare disease drug Tavneos and called for its voluntary removal, the pharma recruited an independent data analysis from Duke researchers to help build the case for the drug's continued market approval.

Original title: “Amgen shores up Tavneos’ FDA defense with Duke data analysis”

The RNA-based medicine is one of a handful of antibody-oligonucleotide conjugates that Novartis acquired last October when it took over neuromuscular-focused Avidity Biosciences.

Original title: “Novartis’ $12B Avidity buy pays dividends with Phase 1/2 muscular dystrophy win”

Strong science, lower costs and growing capital networks are putting Spain and Portugal on the biotech investment map, even as structural bottlenecks persist, according to two investors.

Original title: “Beyond sunshine: Iberia’s biotech moment has arrived with developing capital networks”

The developer of a leading PD-1/VEGF cancer drug cited “market conditions” for the cancellation. Its shares have struggled to break out following data milestones.

Original title: “Summit pulls $500M share sale a day after announcing it”

The staffing changes will focus resources on work that creates the highest impact for patients, according to Genentech. The number of employees affected is unknown, but longtime veteran Vishva Dixit is out.

Original title: “Genentech R&D layoffs hit top exec who’s been with the biotech nearly 30 years”

The data showed that del-brax, an “antisense oligonucleotide conjugate” being tested against a muscle-wasting disease, met its primary endpoint in a Phase 1/2 study.

Original title: “Novartis RNA drug acquired in $12B Avidity deal notches a trial win”

Biotechs are benefitting from the AI tech frenzy and inflation, but validated pipelines and careful planning are still key to the recent record-setting IPOs, experts say.

Original title: “Sky-high Parabilis, Kailera IPOs spur optimism—but only for derisked biotechs”

New data suggest Imaavy could be an effective treatment for autoimmune anemia. Elsewhere, Enliven detailed data for a Merck leukemia rival and MBX hyperparathyroidism drug hit its goal.

Original title: “J&J looks to widen Imaavy’s use; $300M backs rare disease drug launch”

The results support Takeda’s long-held belief in zasocitinib’s superiority and could help it gain a commercial advantage over Bristol’s therapy.

Original title: “Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test”

In this episode of Denatured, you'll be hearing from Hannah Franklin, associate at Biovance Capital and Pablo Gabriel Cironi Lopez, director of life science investment at Caixa Capital Risc as they discuss the rise of Southern Europe’s biotech ecosystem.

Original title: “Portugal, Spain and the new biotech frontier”

For the second time in 2026, the number of biopharma professionals affected by made or projected workforce reductions rose year over year. In May, layoffs spiked nearly 50%, mainly due to Takeda and BioNTech axing a combined 6,360 employees.

Original title: “May layoffs hit nearly 7,000, with most cuts from Takeda, BioNTech”

Just 23% of respondents to a BioSpace LinkedIn poll expect the biopharma job market will rebound in 2026. Three experts discuss when they see a turnaround happening and how increasing emphasis on cost efficiency is impacting hiring practices.

Original title: “The wait continues: pressure to operate lean among factors behind slow job market”